http://www.tradingmarkets.com/.site/news/Stock%20News/1709116/
Jun 24, 2008 (M2 PRESSWIRE via COMTEX) -- MXWL | Quote | Chart | News | PowerRating -- BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Cyberonics Inc. (NASDAQ: CYBX), ICx Technologies Inc. (NASDAQ: ICXT), Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ), Maxwell Technologies Inc. (NASDAQ: MXWL), Harris & Harris Group Inc. (NASDAQ: TINY), China Biopharma Inc. (OTCBB: CBPC). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
Cyberonics Inc. (NASDAQ: CYBX | Quote | Chart | News | PowerRating) a neuromodulation company, engages in the design, development, manufacture, and marketing of medical devices that provide vagus nerve stimulation (VNS) therapy for the treatment of epilepsy and other debilitating neurological or psychiatric diseases, and other disorders. The VNS therapy system consists of an implantable generator that delivers an electrical signal to an implantable lead attached to the left vagus nerve, as well as a bipolar lead, a programming wand and software, and a tunneling tool. The company sells its products through direct sales force in the United States, as well as through independent distributors in Europe, Asia, South Africa, Australia, Mexico, South America, and Canada. Cyberonics was founded in 1987 and is headquartered in Houston, Texas. With 27.39 million shares outstanding and 4.14 million shares declared short as of May 2008, there is a failure to deliver in shares of CYBX. According to quarterly data provided by the SEC, there were still 13,412 shares of CYBX that were failing-to-deliver as of September 28, 2007.
ICx Technologies Inc. (NASDAQ: ICXT | Quote | Chart | News | PowerRating) and its subsidiaries engage in the development and integration of sensor technologies for homeland security, force protection, and commercial applications. The company operates through three segments: Detection, Surveillance, and Solutions. The Detection segment develops products, and conducts research and development in the areas of chemical, biological, radiation, nuclear, and explosives detection. This segment offers Fido explosive detectors, IdentiFINDER and Interceptor radiation detectors, AirSentinel bioaerosol sensors, and Griffin gas chromatography/mass spectrometry line of products. The Surveillance segment provides products and services for perimeter security and wide area surveillance. Its products include Cerberus and SkyWatch towers; thermal imaging cameras, including DefendIR and Orion; STS line of radar products; and MarkIR, an infrared sensors product. The Solutions segment integrates the company's technologies and products to provide single source solutions that address various customer specific security and surveillance needs. This segment offers Cameleon camera control systems; Cameleon ITS transportation management software; StarWatch security command and control software; and Callisto, a non-security related product for process management of various supervisory control and data acquisition applications. The company serves federal agencies; various state and local governments and agencies; and private sector customers in the United States and internationally. It also offers products, components, and sub-systems to integrators in the security and defense industries. The company sells its products through direct sales force, sales representatives, value added resellers, and system integrators. ICx Technologies, Inc. was founded in 2003 and is headquartered in Arlington, Virginia. With 33.71 million shares outstanding and 808,900 shares declared short as of May 2008, there is a failure to deliver in shares of ICXT.
Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ | Quote | Chart | News | PowerRating) focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its marketed and approved products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Luvox CR, an extended release formulation of fluvoxaminefor, which is a selective serotonin reuptake inhibitor for the treatment of obsessive compulsive disorder and social anxiety disorder; and Antizol, an antidote for suspected or confirmed ethylene glycol or methanol poisonings in humans. The company's clinical development pipeline comprises JZP-6, a phase III clinical trial product for the treatment of fibromyalgia; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder that is in phase II clinical trial; JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients, which is in phase II clinical trial; and JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome that is in phase I/II clinical trial. Jazz Pharmaceuticals has a product license agreement with Solvay Pharmaceuticals, Inc. to market Luvox CR and Luvox in the United States; and with GlaxoSmithKline to purchase worldwide rights to the active pharmaceutical ingredient in JZP-4. The company was founded in 2003 and is headquartered in Palo Alto, California. With 24.62 million shares outstanding and 2.37 million shares declared short as of May 2008, there is a failure to deliver in shares of JAZZ. According to quarterly data provided by the SEC, there were still 11,169 shares of JAZZ that were failing-to-deliver as of September 28, 2007.
Maxwell Technologies Inc. (NASDAQ: MXWL | Quote | Chart | News | PowerRating) engages in the development, manufacture, and marketing of energy storage and power delivery products. It offers BOOSTCAP ultracapacitor cells, and multi-cell packs and modules for applications in multiple industries, including transportation, automotive, telecommunications, energy, consumer, and industrial electronics; and CONDIS high-voltage capacitors comprising grading and coupling capacitors, and capacitive voltage dividers that are used to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution, and measurement of high-voltage electrical energy. The company also offers radiation-mitigated microelectronic products, including power modules, memory modules, and single board computers for space and satellite applications. Maxwell Technologies markets and sells its products through direct and indirect sales organizations in North America, Europe, and Asia. The company was founded in 1965. It was formerly known as Maxwell Laboratories, Inc. and changed its name to Maxwell Technologies, Inc. in 1996. The company is headquartered in San Diego, California. With 20.82 million shares outstanding and 2 million shares declared short as of May 2008, there is a failure to deliver in shares of MXWL. According to quarterly data provided by the SEC, there were still 81,580 shares of MXWL that were failing-to-deliver as of September 28, 2007.
Harris & Harris Group Inc. (NASDAQ: TINY | Quote | Chart | News | PowerRating) is a venture capital firm specializing in seed, start up, and mid venture investments. It primarily invests in tiny-technology-enabled companies with a focus on nanotechnology, microsystems, and microelectromechanical systems technology. Harris & Harris Group, Inc. was founded in 1981 and is based in New York, New York. With 23.31 million shares outstanding and 1.01 million shares declared short as of May 2008, there is a failure to deliver in shares of TINY. According to quarterly data provided by the SEC, there were still 11,575 shares of TINY that were failing-to-deliver as of September 28, 2007.
China Biopharma Inc. (OTCBB: CBPC | Quote | Chart | News | PowerRating) is a biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its local presents and the relationship with local Chinese bio-pharmaceutical companies and international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. With 159.38 million shares outstanding and 1.54 million shares declared short as of May 2008, there is a failure to deliver in shares of CBPC. According to quarterly data provided by the SEC, there were still 747,824 shares of CBPC that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,000,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
0 件のコメント:
コメントを投稿